相关实验视频
Updated: Feb 26, 2026

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
9.7K
关于喘过敏原免疫治疗的最新情况
1University of Rochester Medical Center, Allergy Immunology Rheumatology Division, Rochester, New York, USA.
Current opinion in pulmonary medicine
|February 24, 2026
概括
过敏原特异性免疫疗法对喘有希望,特别是在患者的子集中. 新的疫苗和方法正在出现,但需要进一步的研究才能在喘管理中得到更广泛的应用.
科学领域:
- 免疫学和过敏学
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对喘的过敏原特异性免疫疗法 (AIT) 的疗效仍然是正在进行的辩论和研究的主题.
- 最近的进展集中在识别患者子集和开发新型疫苗配方上.
研究的目的:
- 审查最近 (2024-2025) 关于喘过敏原免疫治疗的出版物.
- 评估目前关于AIT在喘管理中的有效性和安全性的证据.
主要方法:
- 在2024年和2025年发表的关于喘的AIT研究的文献综述.
- 对临床试验结果,遗传关联和新兴疫苗技术的分析.
主要成果:
- 家庭灰尘虫免疫疗法在一组具有特定遗传变异 (17q12-21染色体) 的患者中显示出积极的结果.
- 虫免疫疗法在鼻腔挑战中产生了负面结果,但显示出有前途的T细胞效应.
- 新的过敏和辅助性疫苗正在开发中,旨在减少注射量和提高安全性.
- 训练有素的免疫疫苗 (细菌溶解物) 显示出降低儿童喘息的潜力.
- 评论表明AIT可以减少喘症状和药物需求,但不是客观的肺功能措施.
- 将生物药物与AIT结合起来可能会提高安全性.
结论:
- 过敏原特异性免疫疗法对过敏性鼻炎和结膜炎有价值,可以安全地用于控制良好的轻度至中度喘.
- 新兴的AIT方法显示出希望,但需要进一步进行实质性调查和验证.
更多相关视频
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
Allergic Reactions
32.6K
Overview
32.6K
Asthma-I: Introduction
3.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.6K
Asthma-IV: Diagnostic and Management
3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Allergic Reactions: Anaphylaxis
62
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
62
Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K

